Levosimendan has an inhibitory effect on platelet function

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Levosimendan is a cardiac inotrope enhancing contractility and causing vasodilation.
• Its effects on platelet function remain largely uncharacterized despite clinical use in heart failure.

Purpose of the Study:

• To investigate the in vitro effect of levosimendan on platelet aggregation.
• To determine if clinically relevant concentrations of levosimendan influence platelet response to agonists.

Main Methods:

• Whole blood from 12 healthy volunteers was incubated with three concentrations of levosimendan (10, 25, 45 ng/ml).
• Platelet aggregation was measured using adenosine diphosphate (ADP) and collagen as agonists.
• Inhibition of platelet aggregation was assessed in platelet-rich plasma after incubation.

Main Results:

• Levosimendan significantly inhibited platelet aggregation induced by both ADP and collagen across all tested concentrations.
• A dose-dependent relationship was observed between levosimendan concentration and the degree of platelet aggregation inhibition.
• The drug also significantly inhibited the secondary aggregation wave induced by ADP.

Conclusions:

• Levosimendan demonstrates a significant inhibitory effect on human platelet aggregation in vitro.
• These findings suggest that levosimendan may modulate platelet function at clinically relevant concentrations.
• Further studies are warranted to explore the clinical implications of levosimendan's antiplatelet effects.